Personalized Cancer Vaccines

We are building the Canadian path to personalized cancer vaccines, and the software to make better therapies.

Our Neoantigen Selection Platform, NSP, provides intelligence on every candidate peptide for each patient, so the tumor mutations most worth turning into medicine rise to the top

Disrupting cancer, one patient at a time.
Contact usSee how NSP works
The Problem

Personalized cancer vaccines show unmatched real clinical promise. Consistent, durable benefit across all patients is the unsolved part.

100%
of the 11 patients who completed treatment developed a targeted T-cell and B-cell immune response in Mount Sinai's PGV001 Phase 1 trial, which used a poly-ICLC adjuvant
44%
of the 126 individual neoantigens administered in that same trial triggered a T-cell response
6 of 13
patients in that trial were still alive at five-year follow-up, and 3 were cancer-free, an early but genuine signal of durability

Cancer remains one of the leading causes of death. Outside of surgery or immunotherapy, targeted therapy usually isn't curative. Several vaccine trials, across peptide, DNA and mRNA platforms, have already produced real, measurable results. The pattern across the field is that immune responses are common; making strong, durable results consistent from patient to patient is the harder problem. Rescue Bio exists to close that gap. See the full evidence base.

The Platform

NSP sits between "here is the tumor" and "here is what we manufacture"

The pipeline runs from sequencing through mutation calling, patient HLA typing, RNA-confirmed candidate generation, multi-dimensional scoring, and a capped, logged peptide pool, ending in human review before manufacturing.

Most pipelines stop at binding and expression

Candidates are usually scored almost entirely on how strongly a peptide binds and how much of it the tumor expresses. It is a real signal, but an incomplete one.

NSP adds a stemness-weighted layer

NSP weights candidates by whether the mutation is present in the tumor's stem-like, treatment-resistant cell population, not just the bulk tumor. It is a bet on preventing recurrence, not only shrinking the tumor today.

Read the full platform explanation.

Lead Indications

Starting where the need is greatest

The company's initial focus is glioblastoma and pancreatic cancer, both essentially incurable once standard therapy is exhausted, with plans to expand into breast, renal and ovarian cancers.